anti-CD19-tLNP-circCAR

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug Nameanti-CD19-tLNP-circCAR
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Circular RNACell and gene therapy > Gene therapy > LNPCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesRiboX Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRiboX Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A